SOURCE-LINKED STUDY SUMMARY
Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial.
Abstract summarizedQuality not appraised
- What was studied
- A double-blind randomized trial tested short-term testosterone efficacy and biochemical recurrence in selected prostate-cancer survivors.
- Who / model studied
- 136 hypogonadal men after prostatectomy for low-grade cancer, with undetectable PSA for at least 2 years.
- Studied dose & schedule
- Testosterone cypionate 100 mg intramuscularly weekly or placebo for 12 weeks.
- What the study found
- Sexual activity increased by 0.91 daily events versus placebo (95% CI 0.56-1.26). Desire, body composition and physical performance improved; erectile function did not. Neither group had biochemical recurrence.
- Limitations & context
- Too small and short to establish long-term cancer safety. Not applicable to high-grade disease, radiation or androgen-deprivation treatment. A published correction addressed baseline testosterone units.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jamainternmed.2026.1343